Search

Your search keyword '"Meserve, Joseph"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Meserve, Joseph" Remove constraint Author: "Meserve, Joseph" Database ScienceDirect Remove constraint Database: ScienceDirect
30 results on '"Meserve, Joseph"'

Search Results

1. Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study

3. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

5. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

6. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis

7. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

9. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease

16. Mo1916 – Effectiveness and Safety of Ustekinumab for Crohn’s Disease in Routine Clinical Practice

17. 334 – Development and Validation of a Clinical Scoring Tool for Predicting Treatment Outcomes with Vedolizumab in Patients with Ulcerative Colitis

18. Mo1867 - Shorter Disease Duration is Associated with Higher Response Rates to Vedolizumab in Crohn's Disease but not Ulcerative Colitis: A Multi-Center Consortium Analysis

19. Sa1726 - Impact of Concomitant Immunomodulator use on Vedolizumab Effectiveness: A Multicenter Consortium Propensity Score-Matched Analysis

20. Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis

21. Sa1701 - A Multicenter Cohort Study to Assess the Safety of Vedolizumab for Inflammatory Bowel Disease

22. 328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis

23. 277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis

24. Mo1785 - Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium

25. Sa1853 - Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium

30. Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice

Catalog

Books, media, physical & digital resources